洛铂联合紫杉醇治疗子宫内膜癌的效果及毒副反应观察

任妞 张晓莉 金伟丽 刘志丹

【摘要】 目的 探究紫杉醇联合洛铂治疗子宫内膜癌的效果及毒副反应观察。

方法 选择2015年1月至2018年1月就诊的子宫内膜癌患者120例，随机分成观察组和对照组，各60例。对照组采用顺铂+紫杉醇进行静脉化疗，观察组采用洛铂+紫杉醇进行静脉化疗。比较两组治疗后临床疗效、治疗期间毒副反应，并随访2年，观察两组生存情况。

结果 治疗后，观察组总有效率为58.33%，对照组为53.33%，两组差异無统计学意义（P>0.05）;治疗期间，两组白细胞下降、血小板减少、周围神经炎的发生率无明显差异（P>0.05），观察组恶心呕吐、肝损害、肾损害发生率低于对照组（P<0.05）;随访2年，观察组的2年总生存率为76.67%，对照组为71.67%，差异无统计学意义（P>0.05）。

结论 洛铂联合紫杉醇与顺铂联合紫杉醇治疗子宫内膜癌均具有较好疗效，能改善患者生存情况，但洛铂联合紫杉醇的毒副反应较轻。

【关键词】 紫杉醇;洛铂;子宫内膜癌;毒副反应

中图分类号：R711.74   文献标志码：A   DOI：10.3969/j.issn.1003-1383.2021.03.009

Observation on efficacy and adverse reactions of lobaplatin combined with  paclitaxel in the treatment of endometrial cancer

REN Niu， ZHANG Xiaoli， JIN Weili， LIU Zhidan

（Department of Obstetrics and Gynecology， No. 989 Hospital of Joint Service Support  Force of Chinese People's Liberation Army， Luoyang 471003， Henan， China）

【Abstract】 Objective To explore the efficacy and adverse reactions of lobaplatin combined with paclitaxel in the treatment of endometrial cancer.

Methods A total of 120 endometrial cancer patients who were treated in hospital from January 2015 to January 2018 were enrolled and randomly divided into observation group and control group， with 60 cases in each group. The control group were given intravenous chemotherapy with cisplatin + paclitaxel， and the observation group were given intravenous chemotherapy with lobaplatin + paclitaxel. And then， the clinical efficacy and side effects were compared between the two groups， and the patients were followed up for 2 years to observe the survival of them.

Results After treatment， the total effective rate was 58.33% in the observation group and 53.33% in the control group， difference was not statistically significant（P > 0.05）. During treatment， there was no statistically significant difference in the incidence of leucocyte decline， thrombocytopenia and peripheral neuritis between the two groups （P > 0.05）. The incidence of nausea and vomiting， liver damage， and kidney damage in the observation group was lower than that in the control group （P < 0.05）. After 2 years of follow-up， 2-year overall survival rate was 76.67% in the observation group and 71.67% in the control group， difference was not statistically significant （P > 0.05）.

Conclusion Both lobaplatin combined with paclitaxel and cisplatin combined with paclitaxel have good curative effects in the treatment of endometrial cancer， and they can improve the survival of patients. However， side reactions of lobaplatin combined with paclitaxel are relatively milder.

【Key words】 paclitaxel; lobaplatin; endometrial cancer; curative effect; side reaction

子宫内膜癌是一种常见女性恶性肿瘤，临床多采用手术治疗，早期患者的生存率较高，但是晚期及复发性耐药性患者预后较差，还需要进行放疗或化疗等辅助治疗，延长患者生命[1]。化疗主要以铂类、紫杉醇及阿霉素类药物为主，顺铂和紫杉醇常联合使用，能够改善肿瘤细胞对紫杉醇的耐药性，有效抗癌，但是其毒副作用较大，预后较差[2]。洛铂为第三代铂类抗癌药物，能够阻碍DNA的复制及转录，从而抑制肿瘤生长增殖，且无明显肾毒性，已用于治疗宫颈癌等疾病[3]。笔者分别采用洛铂+紫杉醇及顺铂+紫杉醇治疗子宫内膜癌患者，比较其疗效及毒副反应，报告如下。